Obiltoxaximab

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia[1][2][3][4].

Product Specifications

CAS Number

[1351337-07-9]

Product Name Alternative

ETI 204

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/obiltoxaximab.html

Purity

99.06

Solubility

H2O

Smiles

[Obiltoxaximab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Nagy CF, et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. Clin Transl Sci. 2017 Jan;10 (1) :12-19.|[2]Yamamoto BJ, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob Agents Chemother. 2016 Sep 23;60 (10) :5796-805.|[3]Hou A W, et al. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection[J]. Annals of Pharmacotherapy, 2017, 51 (10) : 908-913.|[4]Yamamoto B J, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax[J]. Antimicrobial agents and chemotherapy, 2016, 60 (10) : 5796-5805.|[5]Biron B, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax[J]. Antimicrob Agents Chemother. 2015 Apr;59 (4) :2206-14.